Does Humana Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is an oral, direct factor Xa inhibitor manufactured by Bristol-Myers Squibb and Pfizer. The FDA granted initial approval in December 2012 for reducing stroke and systemic embolism risk in adults with nonvalvular atrial fibrillation, and later for deep vein thrombosis (DVT) treatment, pulmonary embolism (PE) treatment, and DVT/PE prophylaxis after hip or knee replacement surgery 1.

Why the Formulary Tier Matters Financially

Insurance formulary placement directly determines what you pay at the pharmacy counter. A Tier 1 generic might cost $5 per month. A Tier 4 non-preferred brand can cost $100 or more. For a patient taking Eliquis twice daily for atrial fibrillation, this difference adds up to hundreds or thousands of dollars per year.

The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced stroke or systemic embolism by 21% compared with warfarin (hazard ratio 0.79; 95% CI 0.66 to 0.95; P<0.001 for superiority) and also reduced major bleeding by 31% (P<0.001) 2. Those outcomes explain why cardiologists strongly prefer Eliquis for many patients and why access barriers created by formulary placement carry real clinical weight.

What Apixaban Treats

The FDA-approved indications covered by most insurance plans include:

• Nonvalvular atrial fibrillation (stroke prevention)
• Acute DVT or PE treatment (10 mg twice daily for 7 days, then 5 mg twice daily)
• Reduction in recurrent DVT or PE risk (2.5 mg twice daily after at least 6 months of treatment)
• Prophylaxis of DVT following hip or knee replacement surgery

Off-label use for antiphospholipid syndrome has been studied, though the TRAPS trial (N=120) found rivaroxaban inferior to warfarin in that population, a finding the FDA cited when recommending against DOACs in triple-positive antiphospholipid syndrome 3.

How Humana Organizes Its Drug Formularies

Humana operates several distinct insurance products, and each carries its own formulary. Understanding which product you have determines where to look for Eliquis coverage.

Medicare Advantage vs. Medicare Part D Stand-Alone Plans

Humana's Medicare Advantage plans bundle hospital, medical, and prescription coverage. Its Prescription Drug Plans (PDPs) are stand-alone Part D offerings for people in Original Medicare. Both types must comply with CMS formulary guidelines, which require that plans cover at least two drugs in each therapeutic category 4.

Eliquis competes in the anticoagulant category alongside warfarin, rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). Because multiple agents exist in this class, Humana plans have flexibility to place Eliquis at a higher tier or apply step therapy.

Humana Commercial and Employer Plans

Humana also administers employer-sponsored and individual commercial health plans. These plans vary far more widely in formulary design than Medicare Part D plans, which face federal standardization requirements. A commercial plan might place Eliquis on a preferred brand tier at $40/month, or it might classify it as a specialty drug requiring 20 to 30% coinsurance, resulting in costs over $200 per fill.

The Humana Pharmacy Drug List

Humana publishes its formulary as the "Humana Pharmacy Drug List" (PDL). The PDL is updated quarterly and is searchable at humana.com. The document lists each covered drug, its tier, any required utilization management (prior authorization, step therapy, quantity limits), and network pharmacy pricing.

Eliquis Tier Placement on Humana Plans

Tier 3 (Preferred Brand) Status

On many Humana Medicare Part D and Medicare Advantage plans, apixaban sits at Tier 3, designated as a preferred brand. In the standard coverage phase, Tier 3 copays on Humana's most common Part D plans range from $42 to $95 per 30-day supply as of 2024 to 2025 plan years, depending on the specific plan.

Tier 4 (Non-Preferred Brand) Status

Some Humana plans, particularly lower-premium options, place Eliquis at Tier 4. Tier 4 cost-sharing is higher, often $100, $115 per 30-day fill before you reach the catastrophic coverage phase. Patients in the coverage gap (the "donut hole") historically faced even higher costs, though the Inflation Reduction Act of 2022 eliminated the donut hole effective January 1, 2025, capping Medicare Part D out-of-pocket spending at $2,000 annually 5.

Verifying Your Specific Plan Tier

Tier placements change yearly. The only reliable method is to enter your plan ID and "apixaban" or "Eliquis" into Humana's drug pricing tool at humana.com, or call Humana member services at 1-800-457-4708. The Medicare Plan Finder at medicare.gov also allows drug-specific cost comparisons across all Part D plans available in your ZIP code 6.

Prior Authorization Requirements for Eliquis on Humana Plans

Prior authorization (PA) means your prescriber must submit clinical documentation before Humana will approve coverage. Many Humana Part D and Medicare Advantage plans require PA for Eliquis.

What Triggers a Prior Authorization Request

Humana's PA criteria for apixaban typically require the prescriber to confirm:

1. The FDA-approved indication (atrial fibrillation, DVT, PE, or surgical prophylaxis)
2. That the patient does not have a mechanical heart valve (apixaban is contraindicated per the FDA label) 7
3. Renal function data, since severe renal impairment affects dosing
4. Body weight (patients <60 kg may qualify for dose reduction to 2.5 mg twice daily alongside age ≥80 years)

How Long PA Approval Takes

Medicare rules require plans to respond to standard PA requests within 72 hours and urgent requests within 24 hours 8. In practice, most Humana PA decisions for Eliquis are returned within 24 to 48 hours when the prescriber submits complete documentation.

What Happens If PA Is Denied

If Humana denies a PA request, the prescriber may:

• Submit a peer-to-peer review request within the plan's appeal window
• File a formal formulary exception or coverage determination request
• Request an expedited appeal citing medical urgency

The American Heart Association has stated that formulary barriers to direct oral anticoagulants (DOACs) "may lead to undertreatment of atrial fibrillation and increased stroke risk," underscoring that PA denials carry genuine harm potential 9.

Step Therapy: Do You Have to Try Warfarin First?

Step therapy (also called "fail-first") requires patients to try a less expensive drug before the plan will cover the preferred agent. Some Humana plans require a trial of warfarin before approving Eliquis coverage.

The Clinical Problem With Warfarin Step Therapy

Warfarin requires frequent INR monitoring, has a narrow therapeutic index, and carries significant dietary and drug interactions. The RE-LY trial (N=18,113) showed dabigatran 150 mg twice daily reduced stroke/systemic embolism versus warfarin (relative risk 0.65; P<0.001 for superiority), and similar data exist for apixaban from ARISTOTLE 10. Forcing a stable patient on a DOAC to switch to warfarin for step therapy purposes is medically unsound in most clinical scenarios.

Step Therapy Protections

The SUPPORT Patients First Act (incorporated into SUPPORT for Patients and Communities Act, signed 2018) added step therapy protections for Medicare Advantage enrollees. Under these rules, a prescriber can request a step therapy exception if:

• The required drug is contraindicated or expected to cause adverse effects
• The patient tried the required drug previously and it was ineffective or caused harm
• The required drug would delay necessary care for a condition that is serious or life-threatening 11

A patient with a documented history of labile INR on warfarin, or a lifestyle making consistent INR monitoring impractical, would generally qualify for a step therapy exception.

Eliquis Cost With Humana: Real Numbers

Standard Coverage Phase (2025)

Under a representative Humana Gold Plus HMO-PD plan for 2025, Eliquis 5 mg (60 tablets, 30-day supply) carries a Tier 3 preferred-brand copay of approximately $47, $95 at preferred network pharmacies. Costs vary by plan and pharmacy network.

The $2,000 Part D Cap Starting 2025

The Inflation Reduction Act restructured Medicare Part D cost-sharing starting January 1, 2025. Once a Part D enrollee reaches $2,000 in out-of-pocket drug costs in a calendar year, they pay $0 for all covered drugs for the rest of that year 5. For patients taking both Eliquis and other expensive medications, this cap represents a meaningful financial protection.

Monthly Payment Option (MMP)

Medicare Part D enrollees may spread their out-of-pocket costs across the calendar year through the Medicare Prescription Payment Plan (formerly called the "smoothing" program). Humana offers this option as required by CMS for plan year 2025. Patients can pay a fixed monthly amount rather than facing a large single-fill expense 12.

The Bristol-Myers Squibb/Pfizer Eliquis Copay Assistance Program

Bristol-Myers Squibb and Pfizer offer a copay savings program that allows eligible commercially insured patients to pay as little as $10 per month for Eliquis. The program is available at eliquis.bmscustomerconnect.com.

Medicare Patients Are Excluded

Federal anti-kickback statutes prohibit pharmaceutical manufacturer copay cards from applying to Medicare-covered prescriptions. Medicare patients (including those in Humana Medicare Advantage or Part D plans) cannot use the BMS/Pfizer commercial copay card. This is not a Humana policy. It is federal law 13.

The Eliquis 360 Support Program

BMS and Pfizer also operate Eliquis 360 Support, a patient assistance program. Low-income patients who meet income and insurance eligibility criteria may qualify for free or reduced-cost Eliquis through this program regardless of insurance type. Patients can enroll at 1-855-ELIQUIS or through their prescriber's office.

State Pharmaceutical Assistance Programs (SPAPs)

Several states operate SPAPs that supplement Medicare Part D cost-sharing for low-income seniors. If you live in a SPAP-participating state and qualify by income, your SPAP may cover all or part of your Eliquis copay on top of what Humana pays 14.

Generic Apixaban: Will It Lower Costs on Humana Plans?

The FDA approved generic apixaban in 2019 following patent litigation settlements. Market entry for generics was scheduled to begin in 2026 under most settlement agreements, though some manufacturers have reached earlier licensing agreements allowing limited generic sales 15.

What Generic Entry Means for Formulary Placement

Once a generic becomes widely available, Part D plans including Humana's are likely to move generic apixaban to Tier 1 or Tier 2, cutting patient costs to $5, $20 per month. The brand-name Eliquis would likely remain at a higher tier or be removed from formulary in favor of the generic. Bioequivalence standards require that FDA-approved generics deliver the same active ingredient at the same dose with the same clinical effect, so the therapeutic outcome should be identical 16.

What the Clinical Guidelines Say About Apixaban

ACC/AHA Atrial Fibrillation Guidelines

The 2023 ACC/AHA/ACCP/HRS Guideline for Diagnosis and Management of Atrial Fibrillation recommends DOACs over warfarin for most patients with nonvalvular AF and a CHA2DS2-VASc score of 2 or greater in men and 3 or greater in women (Class I recommendation, Level of Evidence A) 17. Apixaban is one of the four DOACs specifically named.

The guideline text states: "For patients with AF and CHA2DS2-VASc score of 2 or greater (men) or 3 or greater (women), oral anticoagulant therapy with a direct oral anticoagulant (DOAC) is recommended in preference to warfarin in patients who are able to be compliant with the medication regimen" 17.

CHEST VTE Guidelines

The American College of Chest Physicians (CHEST) 2021 VTE guidelines recommend apixaban or rivaroxaban over warfarin for treatment of acute DVT or PE in patients without cancer, based on trial evidence from AMPLIFY (N=5,395), which showed apixaban was noninferior to conventional therapy for recurrent VTE (2.3% vs. 2.7%; relative risk 0.84; 95% CI 0.60 to 1.18) and produced significantly less major bleeding (0.6% vs. 1.8%; P<0.001) 18.

HealthRX Formulary Navigation Framework for Eliquis on Humana Plans:

| Step | Action | Timeline | |---|---|---| | 1 | Look up your plan formulary tier and PA requirements at humana.com | Day 0 | | 2 | Prescriber submits PA with INR history, indication, renal function | Day 0 to 1 | | 3 | If PA denied, request peer-to-peer or file formulary exception | Within 60 days of denial | | 4 | If step therapy required and contraindicated, submit step therapy exception with clinical documentation | Same day as denial | | 5 | If Medicare patient, enroll in Medicare Prescription Payment Plan if cost is a barrier | Open enrollment or SEP | | 6 | If commercial patient, activate BMS/Pfizer $10/month copay card | Before first fill | | 7 | Verify generic apixaban availability at your pharmacy annually | Each January |

How to Check Whether Your Specific Humana Plan Covers Eliquis Today

Online Drug Finder Tool

Go to humana.com and select "Find a Drug." Enter your Humana member ID or plan name, then search "apixaban" or "Eliquis." The tool returns your plan-specific tier, copay, and any utilization management requirements. Because formularies update quarterly, checking at the start of each year and each quarter is worthwhile.

Medicare Plan Finder

At medicare.gov/plan-compare, you can enter your ZIP code, current drugs including Eliquis dosage, and preferred pharmacies to compare out-of-pocket costs across every Part D and Medicare Advantage plan available to you. The tool ranks plans by estimated annual drug cost, making it straightforward to find the plan where Eliquis costs least 6.

Calling Member Services

Humana's Part D member services line is 1-800-457-4708 (TTY 711). Representatives can confirm real-time formulary status, explain PA criteria, and initiate a coverage determination request on the spot. Ask specifically whether your plan uses step therapy for apixaban and what the PA approval criteria require.

Asking Your Pharmacist

A Humana network pharmacist can run a real-time adjudication that shows exactly what your copay will be before you pay. If PA is flagged, the pharmacist's system will display the reason code so your prescriber knows precisely what documentation to submit.

What to Do If Humana Denies Coverage for Eliquis

File a Formulary Exception

A formulary exception asks the plan to cover a drug not on its formulary, or to cover a drug at a lower tier. For Medicare plans, Humana must respond to a standard exception request within 72 hours and an expedited request within 24 hours. Your prescriber must submit a statement explaining why the lower-tier alternative (such as warfarin) is not appropriate for your clinical situation 19.

Appeal Through Medicare

If Humana denies the exception, you can appeal through Medicare's five-level appeals process:

1. Redetermination by Humana
2. Reconsideration by an independent review entity (IRE)
3. ALJ hearing (if amount in controversy exceeds $180 in 2025)
4. Medicare Appeals Council review
5. Federal district court review

Statistics from CMS show that beneficiaries who appeal Part D denials succeed at the IRE level approximately 40% of the time when physician documentation is complete 20.

Contact Your State Insurance Commissioner

State insurance commissioners handle complaints about commercial health plan formulary practices. For Medicare Advantage plans, the State Health Insurance Assistance Program (SHIP) provides free counseling. Locate your SHIP at shiphelp.org 21.

Dosing Reference: Eliquis by Indication

Knowing the approved dose matters because Humana's quantity limits are tied to FDA-labeled dosing.

| Indication | Dose | Duration | |---|---|---| | AF stroke prevention (standard) | 5 mg twice daily | Ongoing | | AF stroke prevention (dose reduction: age ≥80, weight <60 kg, or SCr ≥1.5 mg/dL, meet 2 of 3) | 2.5 mg twice daily | Ongoing | | Acute DVT/PE treatment | 10 mg twice daily x 7 days, then 5 mg twice daily | Minimum 6 months | | DVT/PE secondary prevention | 2.5 mg twice daily | After ≥6 months of treatment | | Hip replacement prophylaxis | 2.5 mg twice daily | 35 days | | Knee replacement prophylaxis | 2.5 mg twice daily | 12 days |

Source: Eliquis FDA prescribing information 7.

Quantity limit rejections at the pharmacy almost always result from a mismatch between the prescribed quantity and the FDA-labeled dosing for the documented indication. If Humana's system flags a quantity limit, the prescriber must specify the indication clearly on the prescription.

Eliquis and Drug Interactions: Why Humana May Flag Concurrent Medications

Apixaban is metabolized primarily by CYP3A4 and is a P-glycoprotein substrate. The FDA label warns that combined P-gp and strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, ritonavir) increase apixaban exposure and may require dose reduction, while combined P-gp and strong CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin) decrease exposure and should be avoided 7.

Humana's pharmacy benefit manager may apply drug utilization review (DUR) edits that flag concurrent dispensing of Eliquis with interacting agents. These edits can delay or pause a fill. Your pharmacist can override a DUR edit after clinical review, or the prescriber can submit documentation confirming the interaction has been evaluated and the combination is intentional and monitored 22.